Jose L. Stephens / Shutterstock.com
The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.
The continued success of a life sciences company hinges upon successful partnerships. There are many corporate transactions involving life sciences IP that necessitate conducting due diligence.
These include engaging team members in the face of a merger or acquisition, an initial public offering, venture capital financing, in-licensing, partnering, co-development, or distribution agreements. Structuring due diligence is entirely dependent upon the objectives.
The third Annual Summit on Life Sciences IP Due Diligence provides a forum for industry stakeholders to master how to cultivate, navigate, and apply the results of an effective and profitable due diligence analysis.
Attendees will benefit from in-depth sessions helping them to:
- Identify criteria that impact the overall value of the deal during the IP valuation process;
- Conduct international legal risk assessments and find appropriate resources for IP due diligence examinations;
- Find funding options to facilitate business expansion and accelerate growth;
- Mitigate the inherent risks presented in life sciences IP due diligence investigations; and
- Negotiate and draft the relevant documents to ensure a detailed, robust and accurate agreement.
There will also be opportunities to network and benchmark strategies with professionals from life sciences companies including Akeba Therapeutics, Alexion Pharmaceuticals, Celgene, Dana-Farber Cancer Institute, Novartis Institutes for BioMedical Research, and Stryker.
LSIPR readers can benefit from a unique opportunity to register here for the event and receive a 10% discount with the code: D10-657-657EX01.
Due diligence, incumbent portfolios, life sciences, mergers and acquisitions, venture capital, initial public offering, Akeba, Alexion, Celgene, Novartis